ArticlePhysics in medicine and biology2021
Learning-based dose prediction for pancreatic stereotactic body radiation therapy using dual pyramid adversarial network.
Article in Physics in medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Deep-Learning-Based 3D Dose Distribution Prediction for VMAT Lung Cancer Treatment Using an Enhanced UNet3D Architecture with Composite Loss Functions.Bioengineering (Basel, Switzerland) · 2026Article
- Deep learning-powered radiotherapy dose prediction: clinical insights from 622 patients across multiple sites tumor at a single institution.Radiation oncology (London, England) · 2025Article
- High-dose-rate Brachytherapy Planning with Dendrite Cross-Attention UNet.Proceedings of SPIE--the International Society for Optical Engineering · 2025Article
- Dose prediction of CyberKnife Monte Carlo plan for lung cancer patients based on deep learning: robust learning of variable beam configurations.Radiation oncology (London, England) · 2024Article
- Novel in-house knowledge-based automated planning system for lung cancer treated with intensity-modulated radiotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
- The complex role of macrophages in pancreatic cancer tumor microenvironment: a review on cancer progression and potential therapeutic targets.Discover oncology · 2024Review
- Deep Learning Applications in Pancreatic Cancer.Cancers · 2024Review
- Abdomen CT multi-organ segmentation using token-based MLP-Mixer.Medical physics · 2023Article
- Deep-learning-driven dose prediction and verification for stereotactic radiosurgical treatment of isolated brain metastases.Frontiers in oncology · 2023Article
- Attention-aware 3D U-Net convolutional neural network for knowledge-based planning 3D dose distribution prediction of head-and-neck cancer.Journal of applied clinical medical physics · 2022Article
- Lung tumor segmentation in 4D CT images using motion convolutional neural networks.Medical physics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Treatment planning for pancreatic cancer stereotactic body radiation therapy (SBRT) is very challenging owing to vast spatial variations and close proximity of many organs-at-risk. Recently, deep learning (DL) based methods have been applied in dose prediction tasks of various treatment sites with the aim of relieving planning challenges. However, its effectiveness on pancreatic cancer SBRT is yet to be fully explored due to limited investigations in the literature. This study aims to further current knowledge in DL-based dose prediction tasks by implementing and demonstrating the feasibility of a new dual pyramid networks (DPNs) integrated DL model for predicting dose distributions of pancreatic SBRT. The proposed framework is composed of four parts: CT-only feature pyramid network (FPN), contour-only FPN, late fusion network and an adversarial network. During each phase of the network, combination of mean absolute error, gradient difference error, histogram matching, and adversarial loss is used for supervision. The performance of proposed model was demonstrated for pancreatic cancer SBRT plans with doses prescribed between 33 and 50 Gy across as many as three planning target volumes (PTVs) in five fractions. Five-fold cross validation was performed on 30 patients, and another 20 patients were used as holdout tests of trained model. Predicted plans were compared with clinically approved plans through dose volume parameters and two-paired t-test. For the same sets, our results were compared with three different DL architectures: 3D U-Net, 3D U-Net with adversarial learning, and DPN without adversarial learning. The proposed framework was able to predict 87% and 91% of clinically relevant dose parameters for cross validation sets and holdout sets, respectively, without any significant differences (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.